| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5304 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2767 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1663 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1335 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 588 | 2021 |
| Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial ID Milligan, MM Gibani, R Sewell, EA Clutterbuck, D Campbell, E Plested, ... Jama 315 (15), 1610-1623, 2016 | 383 | 2016 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 331 | 2021 |
| Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison M Ainsworth, M Andersson, K Auckland, JK Baillie, E Barnes, S Beer, ... The Lancet Infectious Diseases 20 (12), 1390-1400, 2020 | 316 | 2020 |
| Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine RP Payne, S Longet, JA Austin, DT Skelly, W Dejnirattisai, S Adele, ... Cell 184 (23), 5699-5714. e11, 2021 | 270 | 2021 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 270 | 2021 |
| A blood atlas of COVID-19 defines hallmarks of disease severity and specificity DJ Ahern, Z Ai, M Ainsworth, C Allan, A Allcock, B Angus, MA Ansari, ... Cell 185 (5), 916-938. e58, 2022 | 160 | 2022 |
| Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern DT Skelly, AC Harding, J Gilbert-Jaramillo, ML Knight, S Longet, A Brown, ... Nature communications 12 (1), 5061, 2021 | 155 | 2021 |
| MAIT cell activation augments adenovirus vector vaccine immunogenicity NM Provine, A Amini, LC Garner, AJ Spencer, C Dold, C Hutchings, ... Science 371 (6528), 521-526, 2021 | 92 | 2021 |
| Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model MM Gibani, E Jones, A Barton, C Jin, J Meek, S Camara, U Galal, E Heinz, ... Nature medicine 25 (7), 1082-1088, 2019 | 55 | 2019 |
| First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on chimpanzee-adenovirus-155 viral … P Cicconi, C Jones, E Sarkar, L Silva-Reyes, P Klenerman, C de Lara, ... Clinical Infectious Diseases 70 (10), 2073-2081, 2020 | 52 | 2020 |
| Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults CA Green, CJ Sande, E Scarselli, S Capone, A Vitelli, A Nicosia, ... Journal of Infection 78 (5), 382-392, 2019 | 38 | 2019 |
| Humoral and cellular immunity to RSV in infants, children and adults CA Green, CJ Sande, C de Lara, AJ Thompson, L Silva-Reyes, ... Vaccine 36 (41), 6183-6190, 2018 | 32 | 2018 |
| Divergent trajectories of antiviral memory after SARS-CoV-2 infection A Tomic, DT Skelly, A Ogbe, D O’Connor, M Pace, E Adland, F Alexander, ... Nature Communications 13 (1), 1251, 2022 | 27 | 2022 |
| Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens SC Moore, B Kronsteiner, S Longet, S Adele, AS Deeks, C Liu, ... Med 4 (3), 191-215. e9, 2023 | 18 | 2023 |
| Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19 CP Kotanidis, C Xie, D Alexander, JCL Rodrigues, K Burnham, A Mentzer, ... The Lancet Digital Health 4 (10), e705-e716, 2022 | 12 | 2022 |
